Games Gina, Hutchison Amber
Harrison School of Pharmacy, Auburn University, 1321 Walker Building (4201F), Auburn, AL 36849.
Consult Pharm. 2013 Oct;28(10):672-5. doi: 10.4140/TCP.n.2013.672.
With the prevalence of diabetes mellitus (DM) increasing, pathologic complications such as diabetic peripheral neuropathy (DPN) are also becoming more common. Of those diagnosed with DM, 10% to 20% of patients suffer from painful DPN. Until recently, only pregabalin and duloxetine possessed Food and Drug Administration (FDA) approval for this condition. However, FDA recently approved tapentadol-ER [extended release] (Nucynta ER) for painful DPN. Tapentadol-ER is an opioid analgesic commonly used for the treatment of moderate-to-severe chronic pain that contains a unique dual mechanism acting as both a weak mu-opiod receptor agonist and norepinephine-reuptake inhibitor. It is by way of this unique dual mechanism that allows for effective analgesic effects with increased tolerability. This new FDA approval provides an additional therapeutic option to treat DPN in symptomatic patients.
随着糖尿病（DM）患病率的上升，诸如糖尿病性周围神经病变（DPN）等病理并发症也越来越常见。在被诊断为糖尿病的患者中，10%至20%的患者患有疼痛性DPN。直到最近，只有普瑞巴林和度洛西汀获得了美国食品药品监督管理局（FDA）针对这种病症的批准。然而，FDA最近批准了缓释他喷他多（Nucynta ER）用于治疗疼痛性DPN。缓释他喷他多是一种常用于治疗中重度慢性疼痛的阿片类镇痛药，它具有独特的双重作用机制，既是一种弱μ-阿片受体激动剂，又是去甲肾上腺素再摄取抑制剂。正是通过这种独特的双重机制，它能够产生有效的镇痛效果，同时耐受性增强。FDA的这一最新批准为有症状的DPN患者提供了另一种治疗选择。
